**Supplemental Table 4**. Changes in serum fatty acids (FA) % from the time of consultation for the acute episode to >1 year post-convalescence in 44 participants1

| Fatty acid2 | Acute dengue episode | Post-convalescence | *P*3 |
| --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |
| SFAs (%) |  |  |  |  |  |  |  |
|  14:0 myristic acid | 0.32 | ± | 0.15 | 0.57 | ± | 0.28 | <0.0001 |
|  15:0 pentadecanoic acid | 0.16 | ± | 0.04 | 0.18 | ± | 0.05 | 0.04 |
|  16:0 palmitic acid | 23.36 | ± | 2.05 | 22.21 | ± | 2.14 | 0.009 |
|  17:0 margaric acid | 0.35 | ± | 0.05 | 0.33 | ± | 0.07 | 0.38 |
|  18:0 stearic acid | 7.93 | ± | 0.78 | 8.27 | ± | 0.98 | 0.06 |
|  20:0 arachidic acid | 0.14 | ± | 0.04 | 0.18 | ± | 0.07 | 0.002 |
|  22:0 behenic acid | 0.29 | ± | 0.11 | 0.36 | ± | 0.12 | 0.008 |
|  24:0 lignoceric acid | 0.17 | ± | 0.17 | 0.28 | ± | 0.17 | 0.01 |
|  Total SFAs | 32.69 | ± | 2.30 | 32.15 | ± | 2.43 | 0.24 |
|  |  |  |  |  |  |  |  |
| MUFAs (%) |  |  |  |  |  |  |  |
|  16:1n-7 palmitoleic acid | 1.63 | ± | 0.53 | 1.84 | ± | 0.59 | 0.03 |
|  18:1n-9 oleic acid | 23.95 | ± | 3.01 | 19.49 | ± | 2.55 | <0.0001 |
|  18:1n-7 *cis*-vaccenic acid | 1.97 | ± | 0.49 | 1.80 | ± | 0.43 | 0.03 |
|  20:1n-9 gondoic acid | 0.21 | ± | 0.08 | 0.17 | ± | 0.05 | 0.002 |
|  24:1n-9 nervonic acid | 0.27 | ± | 0.20 | 0.20 | ± | 0.19 | 0.06 |
|  Total MUFAs | 28.11 | ± | 3.47 | 23.52 | ± | 2.87 | <0.0001 |
|  |  |  |  |  |  |  |  |
| n-3 PUFAs (%) |  |  |  |  |  |  |  |
|  18:3n-3 α-linolenic acid | 0.37 | ± | 0.12 | 0.49 | ± | 0.16 | <0.0001 |
|  20:5n-3 EPA | 0.28 | ± | 0.16 | 0.34 | ± | 0.15 | 0.03 |
|  22:5n-3 DPA | 0.41 | ± | 0.18 | 0.49 | ± | 0.14 | 0.01 |
|  22:6n-3 DHA | 1.93 | ± | 1.01 | 1.67 | ± | 0.49 | 0.14 |
|  Total long chain n-3 PUFAs4 | 2.61 | ± | 1.09 | 2.50 | ± | 0.61 | 0.56 |
|  Total n-3 PUFAs | 3.12 | ± | 1.10 | 3.10 | ± | 0.62 | 0.92 |
|  |  |  |  |  |  |  |  |
| n-6 PUFAs (%) |  |  |  |  |  |  |  |
|  18:2n-6 linoleic acid | 26.76 | ± | 4.04 | 29.40 | ± | 4.23 | <0.0001 |
|  18:3n-6 γ-linolenic acid | 0.11 | ± | 0.07 | 0.28 | ± | 0.25 | <0.0001 |
|  20:2n-6 EDA | 0.21 | ± | 0.11 | 0.23 | ± | 0.11 | 0.39 |
|  20:3n-6 dihomo-γ-linolenic acid | 1.24 | ± | 0.36 | 1.79 | ± | 0.43 | <0.0001 |
|  20:4n-6 arachidonic acid | 6.08 | ± | 1.31 | 6.84 | ± | 1.33 | 0.003 |
|  22:4n-6 adrenic acid | 0.42 | ± | 0.46 | 1.38 | ± | 1.23 | <0.0001 |
|  Total long chain n-6 PUFAs5 | 7.96 | ± | 1.47 | 10.25 | ± | 2.26 | <0.0001 |
|  Total n-6 PUFAs | 34.82 | ± | 4.71 | 39.93 | ± | 4.19 | <0.0001 |
|  |  |  |  |  |  |  |  |
| 18:2n-7*ct* CLA (%) | 0.06 | ± | 0.06 | 0.10 | ± | 0.16 | 0.14 |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| *trans*-FA (%) |  |  |  |  |  |  |  |
|  16:1n-7 *trans* | 0.25 | ± | 0.30 | 0.21 | ± | 0.07 | 0.34 |
|  18:1 *trans* | 0.53 | ± | 0.58 | 0.53 | ± | 0.43 | 0.99 |
|  18:2 *trans* | 0.42 | ± | 0.36 | 0.47 | ± | 0.20 | 0.44 |
|  Total *trans*-FA | 1.20 | ± | 1.01 | 1.21 | ± | 0.65 | 0.98 |
|  |  |  |  |  |  |  |  |
| Ratios |  |  |  |  |  |  |  |
|  Stearoyl-coA-desaturase 18:1n-9/18:0 | 3.05 | ± | 0.49 | 2.40 | ± | 0.46 | <0.0001 |
|  Elongase 18:1n-7/16:1n-7 | 1.44 | ± | 1.04 | 1.05 | ± | 0.37 | 0.009 |
|  Δ6-desaturase 18:3n-6/18:2n-6 | 0.004 | ± | 0.003 | 0.010 | ± | 0.010 | 0.0002 |
|  Δ5-desaturase 20:4n-6/20:3n-6 | 5.20 | ± | 2.06 | 3.99 | ± | 1.05 | 0.0002 |
|  |  |  |  |  |  |  |  |

**Footnotes to Supplemental Table 4**

1 Mean ± SD.

2 SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; EDA, eicosadienoic acid; CLA, conjugated linoleic acid.

3 Test for the mean change in FA percentage weight concentrations from the acute episode to post-convalescence, from a repeated measurements linear regression model with an independent covariance matrix to account for the intra-subject correlation of measurements.

4 Sum of 20:5n-3 EPA, 22:5n-3 DPA, and 22:6n-3 DHA.

5 Sum of 20:2n-6 EDA, 20:3n-6 dihomo-γ-linolenic acid, 20:4n-6 arachidonic acid, and 22:4n-6 adrenic acid.